tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: TRACON Pharmaceuticals (TCON), Immunocore Holdings (IMCR) and Tenaya Therapeutics (TNYA)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on TRACON Pharmaceuticals (TCONResearch Report), Immunocore Holdings (IMCRResearch Report) and Tenaya Therapeutics (TNYAResearch Report) with bullish sentiments.

TRACON Pharmaceuticals (TCON)

H.C. Wainwright analyst Edward White reiterated a Buy rating on TRACON Pharmaceuticals today and set a price target of $12.00. The company’s shares closed last Wednesday at $2.07.

According to TipRanks.com, White has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -14.9% and a 33.3% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for TRACON Pharmaceuticals with a $9.00 average price target.

See today’s best-performing stocks on TipRanks >>

Immunocore Holdings (IMCR)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Immunocore Holdings today and set a price target of $80.00. The company’s shares closed last Wednesday at $53.95, close to its 52-week high of $56.80.

According to TipRanks.com, Trucchio has 0 stars on 0-5 stars ranking scale with an average return of -8.7% and a 40.8% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Arrowhead Pharmaceuticals, and Milestone Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Immunocore Holdings with a $72.50 average price target, implying a 34.3% upside from current levels. In a report issued on August 2, BTIG also initiated coverage with a Buy rating on the stock with a $85.00 price target.

Tenaya Therapeutics (TNYA)

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Tenaya Therapeutics, with a price target of $25.00. The company’s shares closed last Wednesday at $5.49, close to its 52-week low of $4.41.

According to TipRanks.com, Pantginis has 0 stars on 0-5 stars ranking scale with an average return of -20.4% and a 31.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Bioline RX Ltd Sponsored ADR, Applied Genetic Technologies, and Lineage Cell Therapeutics.

Currently, the analyst consensus on Tenaya Therapeutics is a Strong Buy with an average price target of $26.25.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on TCON:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More